Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, ...
These RNA molecular switches were created by a new combinatorial strategy termed 'allosteric selection,' which favors the emergence of ribozymes that rapidly self-cleave only when incubated with ...
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
Chicago-based Vanqua Bio’s Parkinson’s disease drug has shown proof-of-concept in a first-in-human study, with the company to ...
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...
GlobalData on MSN1d
InnoCare’s Phase II psoriasis therapy trial meets primary endpointInnoCare Pharma has announced that its Phase II clinical study of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for ...
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the ...
Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA ...
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
The regulation and remodeling of the tumor microenvironment (TME) are closely associated with how cancers typically progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback